Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders

NCT03946111 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
3
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Yale University

Collaborators